Bezafibrate improves bacterial lipopolysaccharide-induced dyslipidemia and anorexia in rats.
Bacterial endotoxin/lipopolysaccharide (LPS)-induced cachexia is characterized by weight loss, anorexia, and a disturbance in lipid metabolism, namely, hypertriacylglycerolemia. The aim of this study in rats with acute endotoxicity induced by an injection of LPS was to investigate whether bezafibrate, a ligand for peroxisome proliferator-activated receptor alpha and a lipoprotein lipase (LPL) activator, improved cachectic conditions, including impaired lipid metabolism. Short-term administration of LPS in the rats resulted in impairment of triacylglycerol clearance in plasma after the intake of fresh cream. In addition, LPS increased whole-body energy expenditure, reduced fasting body weight and caused anorexia in the rats. Bezafibrate treatment resulted in significant improvements in LPS-induced dyslipidemia and anorexia, but had no effect on energy expenditure, respiratory quotient, or fasting body weight in the endotoxic rats. Administration of LPS was also associated with a decrease in the level of messenger RNA (mRNA) expression for LPL in white adipose tissue and skeletal muscle and an increase in the mRNA levels for uncoupling protein 3 in skeletal muscle. Bezafibrate treatment reversed the decline in LPL mRNA levels in white adipose tissue but not in the skeletal muscle tissue of the rats. The enhanced uncoupling protein 3 mRNA level in the endotoxic rats was not affected by bezafibrate treatment. Plasma concentration of leptin was increased by short-term LPS treatment. Bezafibrate decreased the level of plasma leptin significantly without affecting the level of leptin mRNA expression. These results suggest that bezafibrate may be an effective drug not only for impaired triacylglycerol metabolism, but also for anorexia in cachectic states induced by bacterial infections.
Harada
Nagakatsu
N
Department of Nutrition and Metabolism, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima City, 770-8503, Japan. harada@nutr.med.tokushima-u.ac.jp
Kusuyama
Akiko
A
Morishima
Masaki
M
Okada
Kazuko
K
Takahashi
Akira
A
Nakaya
Yutaka
Y
D000818:Animals; D000855:Anorexia / Q000139:chemically induced / Q000188:drug therapy*; D001629:Bezafibrate / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D001798:Blood Proteins / Q000032:analysis; D015152:Blotting, Northern; D001835:Body Weight; D050171:Dyslipidemias / Q000139:chemically induced / Q000188:drug therapy*; D004734:Energy Metabolism; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007473:Ion Channels / Q000235:genetics; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008071:Lipoprotein Lipase / Q000235:genetics; D008297:Male; D024101:Mitochondrial Proteins / Q000235:genetics; D009124:Muscle Proteins / Q000032:analysis; D009929:Organ Size; D012333:RNA, Messenger / Q000235:genetics; D051381:Rats; D017208:Rats, Wistar; D000071247:Uncoupling Protein 3
D001786:Blood Glucose; D001798:Blood Proteins; D000960:Hypolipidemic Agents; D007473:Ion Channels; D008070:Lipopolysaccharides; D024101:Mitochondrial Proteins; D009124:Muscle Proteins; D012333:RNA, Messenger; C000604394:Ucp3 protein, rat; D000071247:Uncoupling Protein 3; D008071:Lipoprotein Lipase; D001629:Bezafibrate